EBS
Emergent BioSolutions Inc. · Healthcare · Market cap $317.9M
Insiders sold $146K net in the last 90 days ·2 sellers, 0 buyers· 2 of 2 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 7, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.3M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Latest filing
Oct 7, 2026
DeGolyer Donald W
Emergent BioSolutions Inc. (EBS) has 45 SEC Form 4 filings (59 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Oct 7, 2026.
Inside the rolling window, 6 insiders at Emergent BioSolutions Inc. reported no open-market purchases and 11 open-market sales totaling $1.3M. The most active filer is Director DeGolyer Donald W with 3 filings. Insiders have net sold $689K over the trailing 6 months. The most recent open-market filing is a sale of 17,800 shares by Director DeGolyer Donald W, dated Oct 7, 2026, worth $126K.
- Industry:Drug Manufacturers - Specialty & Generic
- CEO:Joseph C. Papa Jr.
- Employees:900
- HQ:Gaithersburg, MD, US
- IPO:2006-11-15
| Source | |||||||
|---|---|---|---|---|---|---|---|
DeGolyer Donald WFirst in 5 months | Director | Sale | 17,800 | $126K | Oct 7 | -12.3% | SEC ↗ |
Williams Paul AnthonyFirst in 3 months | SVP, Products Business | Sale | 3,000 | $20K | Oct 5 | -14.4% | SEC ↗ |
Williams Paul AnthonyFirst in 3 months | SVP, Products Business | Sale | 3,000 | $25K | Jul 2 | -25.1% | SEC ↗ |
Dayal Sujata TyagiFirst in 6 months | Director | Sale | 13,761 | $116K | May 4 | -27.4% | SEC ↗ |
DeGolyer Donald WFirst in 6 months | Director | Sale | 15,481 | $130K | May 4 | -27.4% | SEC ↗ |
Zoon Kathryn CFirst filing | Director | Sale | 17,202 | $144K | May 4 | -27.4% | SEC ↗ |
Katkin KeithFirst filing | Director | Sale | 15,481 | $128K | May 4 | -27.4% | SEC ↗ |
Williams Paul AnthonyFirst filing | SVP, Products Business | Sale | 4,000 | $34K | Apr 3 | — | SEC ↗ |
Richard RonaldFirst filing | Director | Sale | 21,984 | $263K | Dec 9 | — | SEC ↗ |
DeGolyer Donald WFirst filing | Director | Sale | 17,801 | $188K | Nov 12 | — | SEC ↗ |
Dayal Sujata TyagiFirst filing | Director | Sale | 8,552 | $86K | Nov 10 | — | SEC ↗ |
Congress trading EBS 13 all-time
- DRep. Stephen CohenOther$1,001 - $15,0002024-12-11
- DRep. Josh S. GottheimerOther$1,001 - $15,0002021-11-05
- DRep. Josh S. GottheimerPurchase$1,001 - $15,0002021-10-18
- DRep. Josh S. GottheimerOther$1,001 - $15,0002021-09-15
- DRep. Josh S. GottheimerOther$1,001 - $15,0002021-02-23
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002020-11-24
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does EBS have?
Emergent BioSolutions Inc. (EBS) has 45 SEC Form 4 filings (59 transaction rows) in the rolling 365-day window, disclosed by 6 distinct insiders. Most recent filing: Oct 7, 2026.
When was the most recent SEC Form 4 filing for EBS?
The most recent Form 4 filing for EBS on Tracefour is dated Oct 7, 2026.
Who is the most active insider at EBS?
The most active SEC Form 4 filer at EBS in the rolling window is Director DeGolyer Donald W, with 3 filings.
What is the net insider flow at EBS over the last 6 months?
Over the trailing 180 days, insiders at EBS have net sold $689K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at EBS in the current window?
Inside the rolling window, insiders at EBS bought $0 and sold $1.3M based on SEC Form 4 filings.
Can I get alerts for EBS insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Emergent BioSolutions Inc. (EBS). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Emergent BioSolutions Inc. is in the Healthcare sector.